Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Juno Research LLC

Neither a doctor nor a teaching hospital

Research payments

$13,142,621

552 payments

Through program year 2025, Juno Research LLC is reported as receiving $13,142,621 in research payments, across 552 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,140,737 107
2024 Research $3,177,293 41
2023 Research $2,071,243 61
2022 Research $1,618,440 49
2021 Research $1,585,042 96
2020 Research $237,781 77
2019 Research $312,085 121

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $10,063,954 142 payments
  2. Genentech, Inc. $856,279 35 payments
  3. Pfizer Inc. $705,839 66 payments
  4. Amgen Inc. $493,394 5 payments
  5. F. Hoffmann-La Roche AG $195,224 20 payments
  6. AbbVie, Inc. $169,311 19 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $159,337 69 payments
  8. Merck Sharp & Dohme Corporation $137,710 75 payments
  9. Sanofi US Services Inc. $104,421 15 payments
  10. Hoffmann-La Roche Limited $83,808 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity $1,058,531 4 payments
  2. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $882,558 4 payments
  3. A Phase 2 Study of Once-Weekly Ly3437943 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $736,712 4 payments
  4. CT-388-104 OW/OB with T2D $699,587 44 payments
  5. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $573,435 5 payments
  6. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $571,256 32 payments
  7. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $562,273 4 payments
  8. A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $519,848 4 payments
  9. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naive Adults With Type 2 Diabetes $490,719 2 payments
  10. A Phase 2, Parallel, Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Insulin Naive Patients With Type 2 Diabetes Mellitus $479,817 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record